

CHINA PHARMA HOLDINGS, INC.

Form 8-K

March 12, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 6, 2018

**CHINA PHARMA HOLDINGS, INC.**

(Exact name of Registrant as specified in charter)

|   |                       |                                      |
|---|-----------------------|--------------------------------------|
| Nevada  | 001-34471             | 73-1564807                           |
| (State or other jurisdiction<br>of Incorporation) | (Commission File No.) | (IRS Employer<br>Identification No.) |

Second Floor, No. 17, Jinpan Road

Haikou, Hainan Province, China 570216

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: +86 898-6681-1730 (China)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On March 6, 2018, China Pharma Holdings, Inc. (the “Company”) received notification from the NYSE American LLC (“NYSE American”) informing the Company that it had regained compliance with NYSE American’s continued listing standards.

The “below compliance” (“BC”) indicator has no longer been disseminated since March 7, 2018, and the Company has been removed from the list of noncompliant issuers on the NYSE American website.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 12, 2018

**CHINA PHARMA HOLDINGS, INC.**

By: /s/ Zhilin Li  
Name: Zhilin Li  
Title: President and Chief Executive Officer